微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2022, Vol. 14 ›› Issue (1): 58-64.doi: 10.3969/j.issn.1674-5671.2022.01.10

• 临床研究 • 上一篇    下一篇

m6A去甲基化酶ALKBH5在肝细胞癌组织中的表达及其临床意义

  

  1. 桂林医学院公共卫生学院广西环境暴露组学与全生命周期健康重点实验室；桂林医学院公共卫生学院；桂林医学院附属医院病理科
  • 出版日期:2022-02-25 发布日期:2022-03-11
  • 通讯作者: 朱小年 E-mail：zhuxiaonian0403@163.com

Expression of m6A demethylase ALKBH5 in hepatocellular carcinoma tissues and its clinical significance

  • Online:2022-02-25 Published:2022-03-11
  • Supported by:
    国家自然科学基金项目（82060607）；广西自然科学基金项目（2020GXNSFDA297010）；桂林医学院大学生创新创业训练计划项目（202010601176）

PDF (PC)

128

赞

摘要： 目的 探讨m6A去甲基化酶烷基化修复蛋白B同源物5（alkylation repair protein B homolog 5，ALKHB5）在肝细胞癌（hepatocellular carcinoma，HCC）组织中的表达及其临床意义。方法 收集2009年1月至2013年8月在桂林医学院附属医院接受肝癌切除术的80例HCC患者的癌组织及其癌旁组织（距病灶>3 cm）的石蜡包埋标本，采用免疫组化法检测ALKBH5的表达水平，并分析其与HCC患者临床病理特征及与预后的关系。结果 在HCC组织中ALKBH5高表达的患者比例明显低于癌旁组织（P=0.001），且与肿瘤大小和血清甲胎蛋白（α-fetoprotein，AFP）水平相关（均P<0.05）。Kaplan-Meier生存分析显示ALKBH5低表达组患者的总生存期（P=0.011）和无复发生存期（P=0.012）均缩短，多因素Cox回归分析显示ALKBH5低表达是影响HCC患者总生存期（HR=1.965，95%CI：1.029~3.751，P=0.041）和无复发生存期（HR=2.201，95%CI：1.046~4.629，P=0.038）的独立危险因素。 结论 ALKBH5在HCC组织中表达下调且低表达患者预后不良，ALKBH5可能是HCC潜在的预后评估指标及治疗靶点。

关键词: 肝细胞癌, ALKBH5, m6A去甲基化酶, 预后

Abstract: Objective To investigate the expression and clinical significance of m6A demethylase alkylation repair protein B homolog 5 (ALKHB5) in hepatocellular carcinoma (HCC) tissues. Methods The paraffin-embedded specimens of cancer tissues and adjacent tissues (>3 cm from the lesion) were collected from 80 HCC patients who underwent hepatectomy in the Affiliated Hospital of Guilin Medical University from January 2009 to August 2013. The expression of ALKBH5 was detected by immunohistochemistry, and its relationship with the clinicopathological characteristics and prognosis of the HCC patients was analyzed. Results The proportion of patients with high expression of ALKBH5 in HCC tissues was significantly lower than that in adjacent tissues (P=0.001), and correlated with the patient's tumor size and serum α-fetoprotein (AFP) levels (all P<0.05). Kaplan-Meier survival analysis showed that the overall survival (P=0.011) and recurrence-free survival (P=0.012) of patients in the low ALKBH5 expression group were shortened. Multivariable Cox analysis showed that the low expression of ALKBH5 was an independent risk factor affecting the overall survival (HR=1.965, 95%CI: 1.029-3.751, P=0.041) and recurrence-free survival (HR=2.201, 95%CI: 1.046-4.629, P=0.038) of HCC patients. Conclusions The expression of ALKBH5 is down-regulated in HCC tissues, and the patients with low expression have poor prognosis, suggesting that ALKBH5 may be a potential prognostic indicator and therapeutic target of HCC.

Key words:  Hepatocellular carcinoma, Alkylation repair protein B homolog 5, m6A demethylase, Prognosis

中图分类号: 

  • R735.7